Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A. Ardizzoni A, et al. Among authors: boni l. J Clin Oncol. 2005 Jan 20;23(3):569-75. doi: 10.1200/JCO.2005.11.140. J Clin Oncol. 2005. PMID: 15659503 Clinical Trial.
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Ardizzoni A, et al. Among authors: boni l. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57. doi: 10.1093/jnci/djk196. J Natl Cancer Inst. 2007. PMID: 17551145
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A. Tiseo M, et al. Among authors: boni l. J Thorac Oncol. 2008 Oct;3(10):1104-11. doi: 10.1097/JTO.0b013e3181861d67. J Thorac Oncol. 2008. PMID: 18827605 Free article.
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A. Tiseo M, et al. Among authors: boni l. Lung Cancer. 2010 Mar;67(3):355-60. doi: 10.1016/j.lungcan.2009.04.021. Epub 2009 May 26. Lung Cancer. 2010. PMID: 19473722
759 results